Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX112 in relapsed/refractory B-cell malignancies
NCT05643742Phase 2Recruiting
- Sponsor
- CRISPR Therapeutics
- Start
- Mar 2023
- Primary completion
- Jan 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of zugocabtagene geleucel in B cell lymphoma, non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), sponsored by CRISPR Therapeutics. Started Mar 2023; status: recruiting.
02
Drugs
zugocabtagene geleucel
03
Conditions
B cell lymphomanon-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05643742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643742.